Literature DB >> 15495077

Vaginal chlorhexidine during labour for preventing maternal and neonatal infections (excluding Group B Streptococcal and HIV).

P Lumbiganon1, J Thinkhamrop, B Thinkhamrop, J E Tolosa.   

Abstract

BACKGROUND: The incidence of chlorioamnionitis occurs in between 8 to 12 women for every 1000 live births and 96% of the cases of chlorioamnionitis are due to ascending infection. Following spontaneous vaginal delivery, 1% to 4% of women develop postpartum endometritis. The incidence of neonatal sepsis is 0.5% to 1% of all infants born. Maternal vaginal bacteria are the main agents for these infections. It is reasonable to speculate that prevention of maternal and neonatal infections might be possible by washing the vagina and cervix with an antibacterial agent for all women during labour. Chlorhexidine belongs to the class of compounds known as the bis-biguanides. Chlorhexidine has antibacterial action against a wide range of aerobic and anaerobic bacteria, including those implicated in peripartal infections.
OBJECTIVES: To evaluate the effectiveness and side-effects of chlorhexidine vaginal douching during labour in reducing maternal and neonatal infections (excluding Group B Streptococcal and HIV). SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group trials register (July 2003), the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 4, 2002), MEDLINE (from 1966 to 2002), EMBASE (from 1980 to 2002), CINAHL (from 1982 to 2002) and LILACS (from 1982 to 2002). SELECTION CRITERIA: Randomized or quasi-randomized trials comparing chlorhexidine vaginal douching during labour with placebo or other vaginal disinfectant to prevent (reduce) maternal and neonatal infections (excluding Group B Streptococcal and HIV). DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trial eligibility and quality, extracted and entered the data into the RevMan software and interpreted the data. A third reviewer analysed and interpreted the data. The fourth reviewer also interpreted the data. MAIN
RESULTS: Three studies (3012 participants) were included. There was no evidence of an effect of vaginal chlorhexidine during labour in preventing maternal and neonatal infections. Although the data suggest a trend in reducing postpartum endometritis, the difference was not statistically significant (relative risk 0.83; 95% confidence interval 0.61 to 1.13). REVIEWERS'
CONCLUSIONS: There is no evidence to support the use of vaginal chlorhexidine during labour in preventing maternal and neonatal infections. There is a need for a well-designed randomized controlled trial using appropriate concentration and volume of vaginal chlorhexidine irrigation solution and with adequate sample size.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15495077     DOI: 10.1002/14651858.CD004070.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  10 in total

Review 1.  Safety and impact of chlorhexidine antisepsis interventions for improving neonatal health in developing countries.

Authors:  Luke C Mullany; Gary L Darmstadt; James M Tielsch
Journal:  Pediatr Infect Dis J       Date:  2006-08       Impact factor: 2.129

2.  New approaches to preventing, diagnosing, and treating neonatal sepsis.

Authors:  Karen Edmond; Anita Zaidi
Journal:  PLoS Med       Date:  2010-03-09       Impact factor: 11.069

3.  Reducing stillbirths: prevention and management of medical disorders and infections during pregnancy.

Authors:  Esme V Menezes; Mohammad Yawar Yakoob; Tanya Soomro; Rachel A Haws; Gary L Darmstadt; Zulfiqar A Bhutta
Journal:  BMC Pregnancy Childbirth       Date:  2009-05-07       Impact factor: 3.007

Review 4.  The use of chlorhexidine to reduce maternal and neonatal mortality and morbidity in low-resource settings.

Authors:  E M McClure; R L Goldenberg; N Brandes; G L Darmstadt; L L Wright; Deborah Armbruster; Robert Biggar; Joyce Carpenter; Michael J Free; Donald Mattison; Matthews Mathai; Nancy Moss; Luke C Mullany; Stephanie Schrag; James Tielsch; Jorge Tolosa; Stephen N Wall; Anne Schuchat; Abdelkrim Smine
Journal:  Int J Gynaecol Obstet       Date:  2007-03-30       Impact factor: 3.561

Review 5.  Vaginal chlorhexidine during labour for preventing maternal and neonatal infections (excluding Group B Streptococcal and HIV).

Authors:  Pisake Lumbiganon; Jadsada Thinkhamrop; Bandit Thinkhamrop; Jorge E Tolosa
Journal:  Cochrane Database Syst Rev       Date:  2014-09-14

6.  Serious and life-threatening pregnancy-related infections: opportunities to reduce the global burden.

Authors:  Courtney A Gravett; Michael G Gravett; Emily T Martin; Jeffrey D Bernson; Sadaf Khan; David S Boyle; Sophia M R Lannon; Janna Patterson; Craig E Rubens; Matthew S Steele
Journal:  PLoS Med       Date:  2012-10-09       Impact factor: 11.069

7.  A review of health system infection control measures in developing countries: what can be learned to reduce maternal mortality.

Authors:  Julia Hussein; Dileep V Mavalankar; Sheetal Sharma; Lucia D'Ambruoso
Journal:  Global Health       Date:  2011-05-19       Impact factor: 4.185

Review 8.  Clean birth and postnatal care practices to reduce neonatal deaths from sepsis and tetanus: a systematic review and Delphi estimation of mortality effect.

Authors:  Hannah Blencowe; Simon Cousens; Luke C Mullany; Anne C C Lee; Kate Kerber; Steve Wall; Gary L Darmstadt; Joy E Lawn
Journal:  BMC Public Health       Date:  2011-04-13       Impact factor: 3.295

9.  What is the result of vaginal cleansing with chlorhexidine during labour on maternal and neonatal infections? A systematic review of randomised trials with meta-analysis.

Authors:  Charlotte Bell; Laura Hughes; Trevor Akister; Vin Ramkhelawon; Amie Wilson; David Lissauer
Journal:  BMC Pregnancy Childbirth       Date:  2018-05-08       Impact factor: 3.007

10.  Reducing neonatal infections in south and south central Vietnam: the views of healthcare providers.

Authors:  Daniele Trevisanuto; Gaston Arnolda; Tran Dinh Chien; Ngo Minh Xuan; Le Thi Anh Thu; Danica Kumara; Ornella Lincetto; Luciano Moccia
Journal:  BMC Pediatr       Date:  2013-04-09       Impact factor: 2.125

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.